"Programmed cell death 1 ligand 2 protein" trang 1 - tải miễn phí từ tailieunhanh
Increase of soluble programmed cell death ligand 1 in patients with chronic hepatitis C

Increase of soluble programmed cell death ligand 1 in patients with chronic hepatitis C
9    63    0
Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: A case report

Programmed cell death-1 blockade in kidney carcinoma may induce eosinophilic granulomatosis with polyangiitis: A case report
6    28    1
Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma

Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
8    1    1
Evaluation of membrane and soluble PD-L1 expression in advanced stage non-small cell lung cancer patients

Evaluation of membrane and soluble PD-L1 expression in advanced stage non-small cell lung cancer patients
9    23    1
Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers

Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers
15    1    1
Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PDL1) production and transport in colon cancer stem cells

Insluin and epithelial growth factor (EGF) promote programmed death ligand 1(PDL1) production and transport in colon cancer stem cells
12    60    1
Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: A case report

Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: A case report
7    1    1
Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma

Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma
10    78    1
Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies

Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies
10    71    1
Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: A meta-analysis

Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: A meta-analysis
11    50    2
Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma

Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma
11    99    1
Immune checkpoint inhibitors-related myocarditis in patients with cancer: An analysis of international spontaneous reporting systems

Immune checkpoint inhibitors-related myocarditis in patients with cancer: An analysis of international spontaneous reporting systems
9    38    1
The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: A metaanalysis

The prognostic and clinicopathological significance of PD-L1 expression in patients with diffuse large B-cell lymphoma: A metaanalysis
12    56    1
Báo cáo khoa học: The silencing of adenine nucleotide translocase isoform 1 induces oxidative stress and programmed cell death in ADF human glioblastoma cells

Báo cáo khoa học: The silencing of adenine nucleotide translocase isoform 1 induces oxidative stress and programmed cell death in ADF human glioblastoma cells
15    48    0
Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice

Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice
13    42    1
Amphotericin B suppresses M2 phenotypes and B7-H1 expression in macrophages to prevent Raji cell proliferation

Amphotericin B suppresses M2 phenotypes and B7-H1 expression in macrophages to prevent Raji cell proliferation
13    97    1
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic nonsmall cell lung cancer TRAP OLIGO study (WJOG11118L)

Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic nonsmall cell lung cancer TRAP OLIGO study (WJOG11118L)
6    38    1
Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: Treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)

Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: Treatment rationale and protocol design of the B-DASH study (WJOG 14720 L)
6    1    1
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma

A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma
5    67    0
Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: A phase I trial

Rituximab in combination with gemcitabine plus cisplatin in patients with recurrent and metastatic head and neck squamous cell carcinoma: A phase I trial
10    21    2